Chile interested in expanding cooperation with St. Petersburg Research Institute

Print 13 September 2017
GMP News

A meeting between the representatives of Instituto de Salud Pública, Chile, and St. Petersburg Research Institute of Vaccines and Serums was held in St. Petersburg.

The Chilean side represented by Pablo Ortiz Diaz, the Managing Finance Director, showed interest in expanding the cooperation with St. Petersburg Research Institute of Vaccines and Serums in assessing the potential for the presence of Russian immunobiological products in the market of Chile and other countries of the region. At the meeting, the parties agreed to sign a framework agreement on cooperation, which would include organizing the supplies of immunobiological products, joint research and development, as well as the creation of talent pool in the area of biotechnology.

“This meeting with Chilean colleagues is an important step in the development of relations both between our countries and across the Latin America. Chile pursues a consistent policy for prevention of viral diseases in population of the country, and the authorities are closely monitoring the implementation of the National Immunization Program and selection of required drugs,” said Stanislav Uiba, the Director General of MECHNIKOV Latin American Biotechnology Institute, after the meeting.

The competencies of Instituto de Salud Pública are especially important for the Russian side because of the project for construction of MECHNIKOV Latin American Biotechnology Institute implemented by St. Petersburg Research Institute of Vaccines and Serums in Nicaragua. Among other things, the activities of the Institute will be aimed at combating dangerous and rare viral diseases in Latin America and the Caribbean.

Source

Return

All Partners

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news